PSMA PET Scan for Prostate Cancer: Imaging & Theranostics Guide

What is PSMA (Prostate-Specific Membrane Antigen)?

Prostate-Specific Membrane Antigen (PSMA) is a type II transmembrane glycoprotein expressed on prostate epithelial cells. It is highly overexpressed (100-1,000x) in prostate cancer cells, especially in high-grade, metastatic, and castration-resistant disease.

PSMA is an ideal target for molecular imaging and therapy because of its high expression on cancer cells and low expression on normal tissues (except salivary glands, kidneys, small intestine).

How does PSMA PET work?

PSMA PET/CT uses a radiolabelled molecule (tracer) that binds to PSMA on prostate cancer cells. The tracer emits positrons, detected by the PET scanner, creating a 3D image of PSMA-expressing cells.

• Patient receives an intravenous injection of the radiotracer
• Uptake time: 60-90 minutes (varies by tracer)
• PET/CT scan takes 20-30 minutes
• PSMA-avid lesions indicate prostate cancer (primary, nodal, metastatic)

Available radiotracers – Ga-68, F-18 DCFPyL, F-18 PSMA-1007

Several PSMA-targeted radiotracers are available, each with different properties:

• Ga-68 PSMA-11 (Gallium-68):
  • Half-life: 68 minutes
  • Pros: Widely available, lower cost
  • Cons: Short half-life requires on-site cyclotron or generator
• F-18 DCFPyL (Pylarify):
  • Half-life: 110 minutes
  • Pros: Longer half-life allows central production and distribution; higher spatial resolution
  • Cons: Slightly higher renal excretion (bladder activity)
• F-18 PSMA-1007:
  • Half-life: 110 minutes
  • Pros: Low urinary excretion (better for pelvic evaluation)
  • Cons: Not FDA-approved in the US

Indications for PSMA PET

PSMA PET is indicated in several clinical scenarios (NCCN guidelines, 2025):

• Initial staging (high-risk or very high-risk localized prostate cancer):
  • Detects pelvic lymph node metastases (N1) and distant metastases (M1b, M1c)
  • Changes management in 30-40% of patients
• Biochemical recurrence (BCR) after radical prostatectomy or radiation:
  • PSA <0.5 ng/mL: detection rate 30-40%
  • PSA 0.5-1.0 ng/mL: detection rate 40-60%
  • PSA 1.0-2.0 ng/mL: detection rate 60-80%
  • PSA >2.0 ng/mL: detection rate >90%
• Patient selection for PSMA-targeted therapy (Lu-177-PSMA):
  • Confirm PSMA expression on metastases (SUVmax >10-15)

PSMA PET vs. conventional imaging

PSMA PET is superior to conventional imaging (CT, bone scan) for detecting prostate cancer metastases:

• Lymph node metastases:
  • CT: 40-60% sensitivity (size-based)
  • PSMA PET: 80-90% sensitivity (functional)
• Bone metastases:
  • Bone scan: 70-80% sensitivity (osteoblastic activity)
  • PSMA PET: 90-95% sensitivity (PSMA expression)
• Visceral metastases (lung, liver):
  • CT: 70-80% sensitivity (size-based)
  • PSMA PET: 80-90% sensitivity (functional)

Interpretation – SUVmax, miTNM staging, pitfalls

Quantitative parameters:

• SUVmax (Standardized Uptake Value): Higher SUVmax suggests more aggressive disease. Primary tumour SUVmax correlates with Gleason score.
• PSMA expression threshold for therapy: SUVmax >10-15 is typically required for Lu-177-PSMA therapy.

miTNM staging (molecular imaging TNM):

• miT1-T4: Primary tumour extent
• miN1: Regional lymph node metastases
• miM1a: Non-regional lymph nodes
• miM1b: Bone metastases
• miM1c: Visceral metastases (lung, liver)

Pitfalls and limitations:

• False positives:
  • Salivary glands, lacrimal glands, small intestine (physiologic uptake)
  • Celiac ganglion, thyroid, adrenal glands
  • Inflammatory conditions (sarcoidosis, tuberculosis)
  • Other cancers (renal cell carcinoma, lung cancer, melanoma)
• False negatives:
  • PSMA-negative prostate cancer (rare, 5-10%)
  • Neuroendocrine differentiation (small cell carcinoma)
  • Very small lesions (<2-3 mm) below PET resolution

PSMA theranostics – Lu-177-PSMA (Pluvicto)

Theranostics combines diagnostic imaging (PSMA PET) with targeted therapy (Lu-177-PSMA). Lu-177-PSMA-617 (Pluvicto) delivers beta radiation to PSMA-expressing cancer cells.

FDA approval (2022):

• Metastatic castration-resistant prostate cancer (mCRPC)
• Progressed after androgen receptor pathway inhibitors (abiraterone/enzalutamide) and taxane-based chemotherapy
• PSMA-PET positive disease (SUVmax >10-15)

Regimen:

• 7.4 GBq (200 mCi) IV every 6 weeks for 4-6 cycles
• Pre-treatment hydration and antiemetics

VISION trial results:

• Median overall survival: 15.3 vs. 11.3 months (control)
• Radiographic progression-free survival: 8.7 vs. 3.4 months
• Response rate: 30-40% PSA decline ≥50%

Side effects:

• Fatigue (40-50%)
• Dry mouth (xerostomia – 30-40%)
• Nausea (20-30%)
• Anaemia, thrombocytopenia (10-20%)

Limitations – false positives, false negatives

Despite its high sensitivity, PSMA PET has limitations:

• False positives (10-15%): Physiologic uptake (salivary glands, small intestine), inflammatory conditions, other cancers
• False negatives (5-10%): PSMA-negative prostate cancer, neuroendocrine differentiation, lesions <2-3 mm
• Cost and availability: PSMA PET is expensive ($2,000-$5,000) and not available at all centres
• Radiation exposure: 5-10 mSv per scan (similar to CT)

Interactive FAQ – PSMA PET scan

---

Disclaimer: This information is for educational purposes and intended for clinicians and researchers. PSMA PET should be interpreted by experienced nuclear medicine physicians.